Introduction {#sec0001}
============

Lung transplantation (LTx) is a life-saving procedure for end stage lung disease. However LTx recipients have a lower long term survival when compared to other solid organ transplants, with a median survival of only 6.5 years ([@bib0001]). Chronic lung allograft dysfunction (CLAD) is the major factor limiting LTx long-term survival and is the result of alloimmune and infection-induced damage to the graft, resulting in allograft failure and death. In LTx recipients, cytomegalovirus (CMV) replication is common and impacts on survival directly through end-organ infection, but is also associated with the development of CLAD ([@bib0002]). Whilst antiviral drugs can effectively limit CMV replication, the dosing duration is largely empirical, side effects including neutropenia are common and indiscriminate dosing are associated with drug resistance ([@bib0003]). Furthermore, prolonged antiviral use can result in inhibition of immune function, warranting an alternative approach to antiviral treatment ([@bib0004]).

Host control of CMV involves both the innate and adaptive immune systems ([@bib0005]), with a well-established contribution of αβ T cells, B cells and Natural Killer (NK) cells. An additional subset with possible contribution in the immune control of CMV are γδ T cells that can provide protection from CMV in murine models ([@bib0006]) and human γδ T cells can kill CMV-infected cells in vitro ([@bib0007]). Following kidney and hematopoietic stem cell transplantation (HSCT), replication of CMV is associated with subset perturbations in the frequencies of circulating γδ T cells. In particular, CMV replication has been linked to an expansion of γδ T cells lacking the TRDV2 gene segment of the γδ T cell receptor (TCR), called Vδ2^neg^ γδ T cells ([@bib0008]), ([@bib0009]). The increased frequency of Vδ2^neg^ γδ T cells following CMV infection is substantial, often resulting in an expansion from 1% to more than 10% of the total circulating T cells ([@bib0010]), similar to that seen for CMV-specific CD8+ T cells ([@bib0011]). However, there has been minimal investigation of the contribution of these γδ T cells in CMV immunity following LTx.

In addition to their TCR, γδ T cells express several receptors that are typically associated with NK cells, including NKG2D, which engages stress-induced receptors such as the MHC class I polypeptide-related sequence (MIC)-A and -B ([@bib0012]). γδ T cells can also express receptors from the CD94-NKG2 family, which recognise the non- classical MHC class I molecule HLA-E ([@bib0013]). Upregulation of CD94-NKG2C (NKG2C) on NK cells has been associated with CMV seropositivity ([@bib0014]), and there are a number of reports describing the contribution of NKG2C+ NK cells in the control of CMV following solid organ and HSCT ([@bib0015], [@bib0016]). Our own studies ([@bib0017]) and those of others ([@bib0018]) have demonstrated expansion of NKG2C+ NK cells following CMV replication post-LTx, further implicating a role for this receptor in immunity to CMV. However, a role for NKG2C in the context of γδ T cells remains largely unexplored.

Here, we longitudinally assessed the phenotype of circulating γδ T cells in LTx recipients at risk of CMV disease and temporally correlated this with CMV replication within 18 months post-LTx. The data suggest that there are changes in the composition of γδ  T cell subsets associated with CMV infection. Thus, clinical monitoring of this compartment might provide a guide for establishing the optimal duration of viral prophylaxis post-LTx. Furthermore, the dramatic increases in the proportion of NKG2C+ Vδ1+ γδ T cells observed post-infection raise the prospect that γδ T cells could be a promising target for future cellular therapy.

Methods {#sec0002}
=======

**Ethics:** All patients gave written informed consent. The study was approved by The Alfred Hospital Ethics Committee (Project 401/13) and The University of Melbourne Human Research Ethics Committee (Project 1238243).

**Participants**: The clinical cohort consisted of 25 CMV at-risk (receiving a CMV seropositive donor and/or were CMV seropositive), adult patients who received a bilateral LTx between March 2014 to October 2016 at The Alfred Hospital, Melbourne. Peripheral blood was collected pre-LTx and at surveillance bronchoscopies (0.5, 1.5, 3, 6, 9, 12 and 18-months post-LTx), separated into peripheral blood mononuclear cells (PBMC) by Ficoll-Paque (GE Healthcare, Sydney, NSW, Australia) and then cryopreserved in 90% FCS/10% DMSO until analysis. All patients were given standard triple immunosuppressant regimen (prednisolone, tacrolimus and azathioprine or mycophenolate).

**CMV prophylaxis, monitoring and treatment**: The patient\'s risk of CMV replication was further grouped into moderate risk (MR, CMV seropositive recipient, n=15) or high risk (HR, CMV seronegative recipient with a CMV seropositive donor, n=10). Most MR patients (12/15 MR) received standard antiviral prophylaxis for 5.5 months, consisting of 2 weeks intravenous ganciclovir (5g/kg body weight), followed by 450 mg twice daily oral valganciclovir. However, only 2/10 high risk recipients were on antiviral prophylaxis for less than 6 months. In the presence of a negative QuantiFERON-CMV assay (QIAGEN, USA), 3/15 MR and 6/10 HR LTx recipients received extended valganciclovir prophylaxis to 11 months post-LTx. Two HR patients received continuous valganciclovir throughout the entire monitoring period. As per protocol, HR recipients also received CMV hyper-immune immunoglobulin (1.5 million units) on day 1, 2, 3, 7, 14, 21 and 28, whilst also on (val)ganciclovir. CMV replication was detected by COBAS Amplicor CMV monitor test (Roche Diagnostic Systems, NSW, Australia) in both the plasma and bronchoalveolar lavage (BAL), with a PCR result \>150 copies per ml (\>137 international units) considered positive. Patients with high level CMV replication in either blood or BAL (\>10,000 copies/ml) were treated with intravenous ganciclovir for 2 weeks (5 mg/kg). Patients with low level infection in blood or BAL (600-10,000 copies/ml) were given oral valganciclovir for 2 weeks.

**Flow cytometry**: Longitudinal samples from a single recipient were analyzed on the same day. Cryopreserved PBMC were rapidly thawed and rinsed in phosphate buffered saline containing 1% FCS and 5 mM EDTA (FACS buffer). PBMC were then stained in 50 μl FACS buffer containing a single antibody cocktail listed in Supplementary Table 1. Following 30-minute incubation with antibody cocktail at 4°C, PBMC were rinsed in FACS buffer, prior to fixing in 100 μL Cytofix (BD Biosciences, USA). Samples were then centrifuged, supernatant removed, and re-suspended in 100 μl FACS buffer. Anti-mouse Ig compensation beads (BD Biosciences) were used for compensation controls for flow cytometry. Flow cytometry analysis was performed using an LSR Fortessa (Becton Dickinson, NJ, USA). Samples were gated on single, CD14-, CD19- live lymphocytes, followed by gating on CD3+, γδ TCR+ and analyzed using FlowJo software (Treestar, San Carlos, USA). Data was excluded from analysis where the proportion of γδ T cells was 0%, or where the number of events was less than 50 cells in γδ T cell gate. Statistical significance was performed with GraphPad Prism. Comparisons between two groups (MR versus HR) was tested using two-tailed Mann-Whitney test, and linear regression analysis was employed for HR, CMV-reactivated samples. Comparisons between four groups (MR and HR recipients with and without CMV replication) was performed with a Kruskal-Wallis test followed by Dunn\'s multiple comparison tests.

**γδ TCR sequencing**: We excluded γδ T cells that were double positive for Vγ9 and Vδ2 from our analysis (Supplementary Figure 1A). Vγ9/Vδ2neg γδ T cells were sorted from 2 HR recipients, one at pre LTx (15,000 cells) and 9 months post-LTx during CMV reactivation (15,000 cells) and for another Vδ1+ γδ T cells at 6 months post LTx (prior to CMV detection, 1,000 cells) and 12 months post-LTx (during CMV reactivation, 2,900 cells). Cells were sorted into RNAlater (Sigma Aldrich). RNA was extracted using an RNAmicro plus kit (Qiagen) according to the manufacturer\'s instructions. Extracted RNA was then used for high throughput deep sequencing of γδ TCRs, using amplicon rescued multiplex (ARM)-PCR. Following initial first-round RT-PCR using high concentrations of gene-specific primers, universal primers were used for the exponential phase of amplification (iRepertoire Inc., Huntsville, USA, patent: WO2009137255A2), allowing deep, quantitative amplification of TCR Gamma (TRG) and TCR Delta (TRD) sequences. All cDNA synthesis, amplification, NGS library preparation were performed using TRG/TRD iRprofile kits (iRepertoire, Inc. Huntsville, USA) and subsequent libraries were pooled and deep sequenced using an Illumina MiSeq (Micromon Genomics, Monash University).

**TCR repertoire data analysis**: V, D and J gene usage and complementarity determining region (CDR) 3 sequences were identified and assigned and tree maps generated using iRweb tools (iRepertoire, Inc, Huntsville, AL, USA). Tree maps show each unique CDR3 as a coloured rectangle, the size of each rectangle corresponds to each CDR3s abundance within the repertoire and the positioning is determined by the V region usage. Analysis of TCR repertoire diversity was measured by D50 metric, this value indicates the percentage of clonotypes required to occupy 50% of the total TCR repertoire from either TRD and TRG repertoires.

Results {#sec0003}
=======

CMV replication post LTx {#sec0004}
------------------------

CMV infection significantly impacts on LTx success. Therefore, a cohort of LTx recipients were assessed for the presence of actively replicating CMV at routine bronchoscopies post- LTx. Prior to transplant, donor and recipient CMV serostatus was assessed and patients were stratified into two groups at risk of CMV reactivation: MR (recipient CMV seropositive, n=15) and HR (recipient CMV seronegative, donor CMV seropositive, n=10). Following LTx, evidence of CMV replication was assessed by quantitative PCR ([Table 1](#tbl0001){ref-type="table"} ). Overall, there was more CMV replication in the blood and/or BAL in the HR group and 8/10 recipients (H3-H10, [Table 1](#tbl0001){ref-type="table"}) showed evidence of viral replication, whereas CMV replication was observed in 7/15 MR recipients (M9-M15, [Table 1](#tbl0001){ref-type="table"}). Of the 2 HR recipients where CMV replication was absent, one was on extended antiviral prophylaxis for 338 days (H1) and the other was treated with valganciclovir for the entire monitoring period (H2). Viral replication was typically first detected at the cessation of antiviral prophylaxis, at 6 months (4 recipients), 8-9 months (5 recipients) or 11-12 months (6 recipients) post-LTx ([Table 1](#tbl0001){ref-type="table"}). Virus was detected at multiple time points for 4 MR (M9, M11, M12, M14) and 4 HR recipients (H7, H8, H9, H10). CMV replication was more frequently observed in the blood of individuals from the HR group (5/10 HR recipients vs 3/15 MR recipients, [Table 1](#tbl0001){ref-type="table"}). Symptomatic CMV infection was observed in 4 individuals, one MR and 3 HR recipients. In MR recipient M12, reduced lung function was observed coincident with high level viral replication in the blood (\>700,000 copies per ml). CMV pneumonitis was observed in HR recipient H7 at 8 months post-LTx, whereas CMV syndrome/gastritis was observed in HR recipients H3 and H4 at 12 months post-LTx ([Table 1](#tbl0001){ref-type="table"}).Table 1CMV PCR ResultsTable 1:Moderate (M) CMV Risk (R+) (n=15)High (H) CMV Risk (D+/R-) (n=10)Extended prophylaxis3 (M3, M4, M7)8 (H1-H6, H8, H10)BAL PCR Results\<150 copies/mlM1-M8, M15H1-H4, H8150-600 copies/mlM9^12,\ 18^, M12^9^, M13^9^H9^12^600-10000 copies/mlM11^18^H6^12^, H7^12^, H10^12^\>10000 copies/mlM9^6^, M10^9^, M11^9^, M12^6^, M14^6^H5^12^, H9^6^Blood PCR Results\<150 copies/mlM1-M10, M13, M14H1, H2, H6150-600 copies/mlM11^9^H7^12^, H8^18^, H10^12^600-10000 copies/mlM12^9,11^, M15^8^H3^12^[\*](#tb1fn1){ref-type="table-fn"}, H4^12^[\*](#tb1fn1){ref-type="table-fn"}, H8^12^, H9^12^\>10000 copies/mlM12^6^[\*](#tb1fn1){ref-type="table-fn"}H5^12^, H7^8^[\*](#tb1fn1){ref-type="table-fn"}, H9^6^[^2][^3]

The proportion of Vδ1+ T cells correlates with pre-LTx CMV serology and increases upon CMV replication {#sec0005}
------------------------------------------------------------------------------------------------------

To determine whether there was an association between CMV infection and circulating γδ T cells, we initially compared the proportion of γδ T cells within PBMC between MR and HR recipients. The gating strategy employed to identify γδT cells is shown in [Figure 1](#fig0001){ref-type="fig"} A. Overall, the proportion of γδ T cells did not differ between the different CMV risk groups at individual time points post-LTx ([Figure 1](#fig0001){ref-type="fig"}B). Stratifying results from HR recipients in whom active CMV replication was detected by PCR, there was a small but significant increase in the proportion of γδ T cells over the first 18 months post-LTx ([Figure 1](#fig0001){ref-type="fig"}C) but not in the 2 HR recipients where CMV replication was not observed (data not shown). Therefore, CMV replication in previously CMV seronegative LTx recipients was associated with relatively minor changes in the overall proportion of γδ T cells in the blood.Figure 1**The proportion of circulating γδ T cells is associated with pre-existing CMV immunity**. A) Flow cytometry plot of gating strategy used to identify γδ T cells in PBMC samples. Dump = channel including CD14, CD19 and Live/Dead Fixable to exclude monocytes, B cells and dead cells, respectively. B) γδ T cell proportions segregated on time-points of sample collection. Each symbol represents a sample within assigned risk group (dark circles-moderate risk; open triangles-high-risk). C) Analysis of the proportion of γδ T cells post-LTx in high-risk recipients who were CMV PCR positive. Joined solid lines indicate changes in an individual recipient on standard antiviral prophylaxis whereas dashed lines between points are changes for high-risk recipients on extended antiviral prophylaxis. Dashed vertical line indicates cessation of standard antiviral prophylaxis. Filled black circles indicate positive CMV PCR in blood, respectively. Stars indicate positive CMV PCR in both blood and BAL. Arrows indicate where CMV replication was observed for H6 and H9 at 12 and 6 months, respectively, but where no sample was available for analysis. wks=weeks, mo=months.Figure 1

To determine whether there were gross changes in the γδ T cell repertoire in the LTx cohort, we initially enumerated the proportion of Vδ1+ and Vδ2+ γδ T cells and found a significantly higher proportion of Vδ1+ cells in CMV seropositive recipients prior to transplant, although there were 3 MR recipients with a notably lower proportion than others ([Figure 2](#fig0002){ref-type="fig"} A). MR recipients maintained higher proportions of Vδ1+ γδ T cells throughout the post-transplant period ([Figure 2](#fig0002){ref-type="fig"}B and [2](#fig0002){ref-type="fig"}C) than HR recipients who remained PCR negative ([Figure 2](#fig0002){ref-type="fig"}C). Furthermore, MR recipients with or without CMV replication both had a higher proportion of Vδ1+ γδ T cells than HR recipients without CMV replication (mean proportion Vδ1+ γδ T cells MR with CMV = 68%, MR without CMV = 65%, HR without CMV = 24%). Without considering timing over the post-LTx period, there was no significant differences between HR recipients that experienced CMV replication to any other group (mean proportion Vδ1+ = 35%). However, in HR recipients in whom CMV replication was confirmed, the proportion of circulating Vδ1+ γδ T cells significantly increased over time post LTx, which was not observed in the two HR individuals on prolonged antiviral treatment ([Figure 2](#fig0002){ref-type="fig"}C and [2](#fig0002){ref-type="fig"}D). These changes were apparent following the cessation of antiviral prophylaxis and occurred prior to or coincident with CMV replication, such that by 18 months post-LTx, more than 60% of circulating γδ T cells were Vδ1+ in the HR recipients in which CMV replication was detected ([Figure 2](#fig0002){ref-type="fig"}D). Therefore, CMV infection results in a skewing in the γδ T cell repertoire towards the Vδ1+ subset.Figure 2**The predominance of Vδ1 chain expression by circulating γδ T cells is associated with CMV immunity.** A) The proportion of Vδ1+ cells within γδ T cell population in moderate and high-risk recipients before transplant. Three moderate risk recipients with a lower proportion of Vδ1 γδ T cells are labelled (M11, M12, M15). \*\* p=0.004, Mann-Whitney test. B) A flow cytometry plot of moderate and high-risk LTx recipients at 2 weeks (wk) and 12 months (mo) post-LTx in whom CMV active replication was detected. Numbers show the proportion of cells within a given gate (gated on γδ T cells). C) The analysis of post-transplant Vδ1 chain usage within γδ T cells. Data shown is from all timepoints post LTx (ticks on x-axis represent 2wk, 6wk, 3mo, 6mo, 9mo, 12mo and 18mo post-LTx). Recipients were stratified by CMV risk group (n=15 moderate and n=10 high-risk recipients) and by whether active CMV replication occurred (CMV PCR Neg or CMV PCR Pos). \* p=0.02, \*\*p=0.003, Dunn\'s multiple comparisons test. D) Analysis of proportion of Vδ1+ γδ T cells post-LTx in high-risk recipients with active CMV replication. Joined solid lines indicate changes in an individual recipient on standard antiviral prophylaxis whereas dashed lines between points are changes for high-risk recipients on extended antiviral prophylaxis. Dashed vertical line indicates cessation of standard antiviral prophylaxis. Filled black circles indicate positive CMV PCR in blood and stars indicate positive CMV PCR in both blood and BAL. Arrows indicate where CMV replication was observed for H6 and H9 at 12 and 6 months, respectively, but where no sample was available for analysis. wks=weeks, mo=months.Figure 2

Vδ1+ γδ T cells show high TCR diversity during CMV replication {#sec0006}
--------------------------------------------------------------

To assess post-LTx changes in γδ TCR repertoire in more detail, we performed a pilot analysis of TCR sequences prior to and during active CMV replication. Given previous findings ([@bib0019]) and our own observations that the archetypal blood Vγ9/Vδ2 are not involved in CMV control ([@bib0020]), we excluded clones that were double positive for Vγ9 and Vδ2, and only sequenced γδ T cells lacking this specific TRG and TRD combination (called Vγ9/Vδ2neg cells, Supplementary Figure 1A). In an HR recipient that had evidence of CMV replication (recipient H7), we used deep sequencing to assess the pre- and post-transplant γδ TCR repertoire. Analysis of the TCR repertoire of Vγ9/Vδ2neg γδ T cells by tree plot found a dramatic expansion of individual clonotypes during CMV replication ([Figure 3](#fig0003){ref-type="fig"} A) and was not a result of differences in sequencing depth between each sample (Supplementary Figure 1B). Moreover, the total number of clonotypes and D50 diversity index sharply increased and the accumulated frequency of the top 20 clonotypes decreased from the pre-transplant repertoire (Supplementary Figure 1C). The flow cytometry data for this recipient indicated that the proportion of Vδ1+ γδ T cells increased from ∼20% pre LTx to more than 50% of γδ T cells during CMV replication, concurrent with a decrease in the proportion of Vδ2+ γδ T cells from ∼40% to ∼10% of γδ T cells over the same time frame (data not shown). Therefore, when filtering on the expanding Vδ1+ fraction for this donor, we observed that the TCR repertoire was surprisingly diverse during CMV replication ([Figure 3](#fig0003){ref-type="fig"}B).Figure 3**High TCR diversity in γδT cells observed post-transplant.** A) Tree maps showing TRG and TRD deep sequencing of Vγ9/Vδ2neg γδ T cells  from a high-risk LTx recipient, prior to LTx and during CMV replication at 9 months post-transplant. Each coloured rectangle represents a unique TCR clonotype (colours do not match between plots). B**)** Clonotype frequency showing diversity within the filtered Vδ1+ T cell fraction of the repertoire presented in A. The top 9 clonotypes pre-LTx are coloured. C) TRG deep sequencing from a second high-risk LTx recipient. Sequencing was from Vδ1+ γδ T cells sorted from 6 and 12 months post-LTx samples, with the 12 month sample coincident with CMV replication. Left panels: Tree maps showing TRG clones within Vδ1+ γδ T cell repertoire at 6 and 12 months post-LTx, with each coloured rectangle representing a unique TCR clonotype (colours do not match between plots). Middle panels: pie charts showing V-region usage within the Vδ1+ γδ T cell repertoire at 6 and 12 months post-LTx. Right panels: The Vγ4 TCR repertoire at 6 and 12 post post-LTx. Individual clonotypes at 6 months are coloured and frequencies of the same clonotypes are shown in the same colour at 12 months (if present).Figure 3

To exclude the possibility that the transplant itself impacted on Vδ1+ diversity rather than CMV replication, we performed deep sequencing on a second HR recipient at two post-LTx timepoints, one prior to CMV replication (6 months post LTx) and one during CMV replication (12 months post-LTx). In this recipient, to focus on the Vδ1+ fraction, Vδ1+ γδ T cells were sorted by flow cytometry and the TRG repertoire analyzed by deep sequencing. A similar reshaping of the repertoire occurred coincident with CMV replication compared to the pre-CMV repertoire, showing a reduction of clonotypes utilizing Vγ9 and an expansion of individual clonotypes utilizing Vγ2, Vγ4 and Vγ5 TCR gene segments, with Vγ4 showing the largest increase ([Figure 3](#fig0003){ref-type="fig"}C). Within the Vγ4 repertoire, there was a significant expansion of diverse clonotypes during CMV replication ([Figure 3](#fig0003){ref-type="fig"}C). Taken together, our pilot sequencing analysis of HR recipients indicates that the pre-CMV clonal diversity of the γδ T cell compartment was similar to that reported for healthy individuals ([@bib0020]), whereas in HR recipients who had active CMV replication, clonal diversity was significantly increased ([Figure 3](#fig0003){ref-type="fig"} and Supplementary Figure 1). In particular our findings suggest that in the post-LTx period coincident with active CMV infection, there is substantial remodeling of the Vδ1+ γδ TCR repertoire and the dynamics of this remodeling involved a dramatic expansion of individual γδ TCR clonotypes into the immune repertoire.

The proportion of NKG2C+ effector γδ T cells increases with CMV replication {#sec0007}
---------------------------------------------------------------------------

Given substantial diversity in TCR repertoires during the post-LTx period in HR recipients, we investigated whether we could identify the expression of a common marker that was indicative of CMV exposure. Previous studies had shown an increase in the proportions of NK cells expressing the NKG2C activating receptor were associated with active CMV replication ([@bib0017]). Therefore, the expression of NKG2C expression on γδ T cells was compared between MR and HR LTx recipients. Akin to NK cells, a higher proportion of NKG2C+ γδ T cells prior to LTx was associated with MR recipients, where the mean proportion of circulating γδ T cells that expressed NKG2C was 40% in MR recipients, in contrast to less than 20% in HR recipients ([Figure 4](#fig0004){ref-type="fig"} A). Interestingly, the same 3 MR recipients with a lower proportion of Vδ1+ cells also had a lower proportion of NKG2C+ γδ T cells (M11, M12 and M15, [Figure 4](#fig0004){ref-type="fig"}A) and flow cytometric analysis revealed that most NKG2C+ γδ T cells were Vδ1+ ([Figure 4](#fig0004){ref-type="fig"}B). Most MR recipients consistently maintained a high proportion of NKG2C+ γδ T cells over the post-LTx period ([Figure 4](#fig0004){ref-type="fig"}B, [4](#fig0004){ref-type="fig"}C) and similar to results for Vδ1+ analysis, HR recipients without CMV replication had significantly lower proportions of NKG2C+ γδ T cells than both MR groups (mean % NKG2C+ γδ T cells in MR without CMV replication = 32%, MR with CMV = 35% versus HR without CMV = 8%, [Figure 4](#fig0004){ref-type="fig"}C). Further analysis of HR recipients with active CMV replication indicated an associated increase in the proportion of NKG2C+ γδ T cells over the post-LTx period (p=0.003), with a mean proportion of NKG2C+ γδ T cells at 2 weeks post-LTx of 9%, increasing to 32% at 18 months post-LTx (mean overall %NKG2C+ post-LTx = 18%, [Figure 4](#fig0004){ref-type="fig"}B and [4](#fig0004){ref-type="fig"}D). Importantly, this increase was observed after the cessation of antiviral prophylaxis and occurred coincident with CMV replication. Moreover, this change was not evident in two HR recipients without CMV replication who were on prolonged antiviral treatment ([Figure 4](#fig0004){ref-type="fig"}C). Therefore, this suggests that the induction of NKG2C on γδ T cells following CMV infection is at least partially dependent on active viral replication.Figure 4**The proportion of NKG2C+ γδ T cells is associated with CMV immunity**. A) Proportion of NKG2C+ γδ T cells of total blood γδ T cells is shown, between moderate and high-risk transplant recipients prior to transplant. Each symbol represents one recipient with mean ± SEM shown. Three moderate risk recipients with a lower proportion of NKG2C+ γδ T cells are labelled (M11, M12, M15). \*\* p=0.0018, Mann-Whitney test. B) A flow cytometry plot of moderate and high-risk LTx recipients at 2 weeks and 12 months post-LTx in whom CMV active replication was detected. Numbers show the proportion of cells within a given gate (gated on γδ T cells). C) Pooled values for the proportion of NKG2C+ γδ T cells from moderate risk and high-risk recipients stratified by absence or presence of CMV replication (CMV PCR Neg or CMV PCR Pos), with individual time-points designated by discrete groups with mean ± SEM shown for each (ticks on x-axis represent 2wk, 6wk, 3mo, 6mo, 9mo, 12mo and 18mo post-LTx). \*p=0.007, \*\*p=0.0004, Dunn\'s multiple comparisons test. D) Analysis of NKG2C+ γδ T cells over time post-transplant in high-risk recipients who experienced active viral replication. Joined solid lines indicate changes in an individual recipient on standard antiviral prophylaxis whereas dashed lines between points are changes for high-risk recipients on extended antiviral prophylaxis. Dashed vertical line indicates cessation of standard antiviral prophylaxis. Filled black circles indicate positive CMV PCR in blood and stars indicate positive CMV PCR in both blood and BAL. Arrows indicate where CMV replication was observed for H6 and H9 at 12 and 6 months, respectively, but where no sample was available for analysis. wks=weeks, mo=months.Figure 4

To better understand whether the remodeling of the γδ T cell compartment was accompanied by changes in phenotypic marker expression post-LTx, γδ T cells were assessed for the expression of CD27 and CD45RA, two receptors used to define naïve (CD27+/CD45RA+) and effector (CD27low CD45RA+) γδ T cells ([@bib0020], [@bib0021]). Prior to LTx, MR recipients had more effector γδ T cells pre-LTx than HR recipients, although the same 3 MR recipients with lower Vδ1+ and NKG2C+ γδ T cells also had a lower proportion of effector γδ T cells ([Figure 5](#fig0005){ref-type="fig"} A). Consistent with previous data, individuals from the MR group maintained higher proportions of effector γδ T cells post LTx ([Figure 5](#fig0005){ref-type="fig"}B, [5](#fig0005){ref-type="fig"}C) and both MR groups had significantly higher proportions of effector γδ T cells than HR patients without CMV replication (MR without CMV replication = 70%, MR with CMV = 67% versus HR without CMV = 25%, [Figure 5](#fig0005){ref-type="fig"}C). In contrast, there was a dramatic proportional increase in CD27low CD45RA+ effector γδ T cells in the HR group that went on to experience an episode of CMV replication ([Figure 5](#fig0005){ref-type="fig"}B, C and D). Overall the proportion of CD27low CD45RA+ γδ T cells in HR recipients with CMV replication was 48%, however at 2 weeks this proportion was 33%, increasing to 90% at 18 months post-LTx. Indeed, the higher proportions of effector γδ T cells was not seen in the HR recipients without CMV replication on extended prophylaxis ([Figure 5](#fig0005){ref-type="fig"}C).Figure 5**Increase in γδ T cells with an effector phenotype is associated with CMV replication in high-risk individuals.** A) The proportion of effector (CD27low CD45RA+) γδ T cells of total blood γδ T cells between CMV moderate and CMV high-risk recipients prior to transplant. Each symbol represents one recipient with mean ± SEM shown. Three moderate risk recipients with a lower proportion of effector γδ T cells are labelled (M11, M12, M15). \*\* p=0.0018, Mann-Whitney test. B) A flow cytometry plot of moderate and high-risk LTx recipients at 2 weeks and 12 months post-LTx in whom CMV active replication was detected. Numbers show the proportion of cells within a given gate (gated on γδ T cells). C) Pooled values for the proportion of effector (CD27low CD45RA+) γδ T cells from moderate risk and high-risk recipients stratified by absence or presence of CMV replication (CMV PCR Neg or CMV PCR Pos), with individual time-points designated by discrete groups with mean ± SEM shown for each (ticks on x-axis represent 2wk, 6wk, 3mo, 6mo, 9mo, 12mo and 18mo post-LTx). \* p=0.002, \*\*p=0.01, Dunn\'s multiple comparisons test. D) Analysis of effector (CD27low CD45RA+) γδ T cells over time post-transplant in high-risk recipients who were CMV PCR positive. Joined solid lines indicate changes in an individual recipient on standard antiviral prophylaxis whereas dashed lines between points are changes for high-risk recipients on extended antiviral prophylaxis. Dashed vertical line indicates cessation of standard antiviral prophylaxis. Filled black circles indicate positive CMV PCR in blood and stars indicate positive CMV PCR in both blood and BAL. Arrows indicate where CMV replication was observed for H6 and H9 at 12 and 6 months, respectively, but where no sample was available for analysis. wks=weeks, mo=months.Figure 5

Our data suggested that CMV replication resulted in an expansion of effector γδ T cells that co-expressed Vδ1 and NKG2C. Indeed, a detailed analysis of 2 HR recipients (H6 and H9) showed similar trends prior to and following CMV replication ([Figure 6](#fig0006){ref-type="fig"} ). Following LTx but prior to CMV replication, the proportions of γδ T cells in the blood were similar in both recipients (∼2% of lymphocytes), which increased following CMV replication to 22% and 7%, in H6 and H9, respectively ([Figure 6](#fig0006){ref-type="fig"}A). In both HR recipients prior to CMV replication, the vast majority of γδ T cells expressed Vδ2 (∼80%) while the proportion that expressed Vδ1 in the circulation was only 14% ([Figure 6](#fig0006){ref-type="fig"}B). Strikingly, following CMV replication, this ratio changed markedly, as the proportion of Vδ1+ γδ T cell increased to 87% and 65% of γδ T cells in H6 and H9 respectively, which was accompanied by a concomitant decrease in the proportion of Vδ2+ γδ T cells, to the point where they were almost absent in recipient H6 ([Figure 6](#fig0006){ref-type="fig"}B). Notably, it was the expanded Vδ1+ γδ T cell population that expressed NKG2C at much higher levels than Vδ2+ γδ T cells and CD3+ non- γδ T cells ([Figure 6](#fig0006){ref-type="fig"}C). Moreover, the proportion of Vδ1+ γδ T cells expressing an effector phenotype (CD27low CD45RA+) increased dramatically following CMV replication; namely from 30% to 100% in H6 and from 15% to 85% in H9 ([Figure 6](#fig0006){ref-type="fig"}D). Although there was also an increase in proportion of effector Vδ2+ γδ T cells in recipient H9 (19% to 54%, [Figure 6](#fig0006){ref-type="fig"}D), this was not to the same extent as Vδ1+ γδ T cells. Moreover, as mentioned above, the overall proportion of Vδ2+ γδ T cells had dramatically decreased following CMV replication in recipient H9. Notably, Vδ2+ γδ T cells were virtually absent in the circulation of recipient H6 following CMV replication ([Figure 6](#fig0006){ref-type="fig"}B). A higher proportion of NKG2C+ γδ T cells also expressed an effector phenotype following CMV replication in both recipient H6 and H9 ([Figure 6](#fig0006){ref-type="fig"}E), likely as a result of the co-expression of NKG2C on Vδ1+ γδ T cells ([Figure 6](#fig0006){ref-type="fig"}C).Figure 6**NKG2C+ Vδ1+ effector γδ T cells are associated with CMV replication**. Flow cytometry plots of high risk recipients (H6 and H9) and a moderate risk recipient (M9), prior to the detection of replicating CMV (Pre CMV: 6 months, 3 months and 6 weeks post-LTx for H6, H9 and M9 respectively) and following the detection of CMV (Post CMV: 18 months, 12 months and 18 months post-LTx for H6, H9 and M9 respectively). A) Proportion of γδ T cells in the blood pre and post CMV detection. Numbers represent γδ T cells as a percentage of total lymphocytes. B) Proportion of Vδ1 and Vδ2 γδ T cells prior to and following the detection of CMV replication. Numbers represent proportion as a percentage of total γδ T cells. C) Expression of NKG2C on Vδ1 (light grey histogram) and Vδ2 (dark grey histogram) γδ T cells, compared to CD3 positive γδ TCR negative T cells (dashed histogram). D) Proportion of Vδ1 (red) and Vδ2 (blue) γδ T cells expressing CD27 and CD45RA prior to and following CMV replication. Numbers represent proportions of cells in each quadrant, with proportions of Vδ1 show in red and Vδ2 in blue. E) Proportion of NKG2C+ γδ T cells expressing CD27 and CD45RA prior to and following CMV replication. Plots are gated on NKG2C+ γδ TCR+ cells. Numbers represent proportions of cells in each quadrant.Figure 6

In order to examine if subtle changes were also present in MR recipients with CMV reactivation, we performed a similar analysis of the co-expression of Vδ1, NKG2C and effector γδ T cell subsets in an MR recipient (M9). Indeed, although the proportion of γδ T cells in the blood did not change prior to and following CMV replication in this MR individual ([Figure 6](#fig0006){ref-type="fig"}A), there was a proportional increase in the Vδ1+ and decrease in Vδ2+ populations following CMV replication ([Figure 6](#fig0006){ref-type="fig"}B). Notably, it was the Vδ1+ subset that expressed NKG2C ([Figure 6](#fig0006){ref-type="fig"}C) and both the Vδ1+ ([Figure 6](#fig0006){ref-type="fig"}D) and the NKG2C+ populations ([Figure 6](#fig0006){ref-type="fig"}E) transitioned to an effector phenotype, whereas the Vδ2+ population lacked NKG2C ([Figure 6](#fig0006){ref-type="fig"}C) and did not possess an effector phenotype ([Figure 6](#fig0006){ref-type="fig"}D). Indeed, an analysis of MR recipients with CMV replication indicated changes in the composition of the γδ T cell compartment. Of particular note were recipients M11 and M15 that had low proportions of pre-LTx Vδ1+/NKG2C+/effector γδ T cells ([Figure 2](#fig0002){ref-type="fig"}A, [4](#fig0004){ref-type="fig"}A and [5](#fig0005){ref-type="fig"}A) but showed dramatic changes following CMV replication (Supplementary Figure 2). Thus, taken together, the data show that CMV replication was associated with the development of effector Vδ1+ NKG2C+ γδ T cell population following LTx.

Discussion {#sec0008}
==========

Our study has found marked changes in circulating γδ T cells following LTx with a profound expansion of Vδ1+ NKG2C+ γδ T cells strongly correlating with CMV replication post-LTx. γδ T cells have previously been shown to expand in response to CMV infection in kidney transplant patients and change the proportion of γδ TCR subtypes ([@bib0022]), from Vδ2+ to Vδ2-, with Vδ1+ cells specifically correlated with CMV immunity ([@bib0020]). Our results suggest this to also be the case in HR LTx recipients following CMV exposure, in keeping with what has been observed in other solid organ transplantation ([@bib0009]). Interestingly, most CMV seropositive recipients had a stable, elevated frequencies of effector Vδ1+ cells, that were similar in the pre-and post LTx period, irrespective of subsequent episodes of CMV replication. In contrast, in HR LTx recipients, there was a marked change in the composition of the γδ T cell population with CMV replication towards a cytotoxic effector phenotype, marked by the loss of CD27 ([@bib0020]). However, 3 CMV seropositive recipients (M11, M12 and M15) had lower frequencies of effector γδ cells and all 3 of these experienced CMV replication. Notably, 2 of these (M11 and M15) showed subsequent changes in composition of γδ T cells following CMV replication, similar to those seen in HR recipients. Interestingly, M11 showed the highest CMV replication in the BAL, whereas for M15 it was in the blood ([Table 1](#tbl0001){ref-type="table"}), indicating that the site of CMV replication did not impact on whether this subset was observed in the circulation. In contrast, recipient M12 failed to show such alterations in the γδ T cell compartment and experienced multiple recurrences of CMV replication at 6, 9 and 11 months post-LTx. It is tempting to speculate that CMV replication not only initiates the expansion of effector γδ cells, but that high levels of this subset protect from further replication. A larger cohort from several transplant centers will verify these findings.

In contrast to previous studies, we did not observe expansion of selected clones in post-LTx period ([@bib0008], [@bib0020], [@bib0023]) but rather we found a substantial increase in TCR diversity with CMV replication post-LTx. Our observations may reflect expanded minor clones or novel thymic emigrants recruited into the immune repertoire in response to CMV. Indeed, a polyclonal CD8+ T cell response to CMV has been observed following umbilical cord blood transplantation ([@bib0024]). It is also possible that this diversity is due to immunological 'space' created by immunosuppression post-transplant or inflammatory cytokines allowing for non-specific expansion of unique clones. This however is unlikely, as it does not explain preferential increased diversity in Vδ1+ cells and moreover Vδ1+ cells are reportedly refractory to expansion by key inflammatory cytokines (IL-12 or IL-18) ([@bib0020]). However, we acknowledge that our sequencing analyzes only 2 HR recipients and requires more HR and MR recipients to draw solid conclusions, which will be a focus of future studies.

Although the Vδ1+ γδ T cell population following CMV replication in LTx had incredibly diverse TCRs, we found the co-expression of NKG2C. Intriguingly, and similar to that observed for NK cells ([@bib0016]), the proportion of NKG2C+ Vδ1+ γδ T cells appeared to remain high and stable following the clearance of actively replicating virus. Although NKG2C expression on Vδ1+ γδ T cells has also been associated with cytotoxicity against HIV-infected CD4+ αβ T cells ([@bib0013]), to our knowledge this is the first study associating the expression of NKG2C on γδ T cells is linked with CMV replication and suggest their role in anti-viral immunity. NKG2C recognizes a monomorphic non-classical MHC class I molecule human leukocyte antigen (HLA)-E. Moreover, NKG2C binds HLA-E presenting the CMV-derived UL40 peptide with a high affinity ([@bib0025]). NKG2C expression on lymphocytes has been directly associated with CMV seropositivity ([@bib0026]) and a higher incidence of CMV replication in the LTx cohort in whom NKG2C gene deletion exists ([@bib0027]). Although TCR ligand(s) for Vδ1+ γδ T cell remain poorly defined, they have not been explicitly linked to CMV infection, but include molecules induced by cellular stress. Although cells can be activated via NKG2C without engagement of TCR ([@bib0028]), their action is likely to be classical HLA-independent, favoring them as good candidates for cellular therapy sourced clinically from a third-party without being HLA-matched to the recipient ([@bib0029]). Moreover, although NKG2C has been largely associated with CMV immunity, it is possible Vδ1+ γδ T cells are effective against other diseases where HLA-E is overexpressed such as EBV-associated cancers ([@bib0030]). Intriguingly, a recent report found an association between the genetic lack of NKG2C and more severe coronavirus 2019 disease (COVID-19) ([@bib0031]). Future research will be required to investigate the functional potential of NKG2C+ γδ T cells in these settings. Moreover, investigations of this subset in the lung allograft itself will be of great benefit in pinpointing their contribution to local CMV immunity.

One drawback of our study was that all the recipients were on (val)ganciclovir post-LTx and that the withdrawal of antiviral prophylaxis could have been responsible for initiating the expansion of this subset rather than active CMV replication. However, most MR and 2 HR recipients ceased antiviral prophylaxis prior to 6 months post LTx, yet the enrichment of NKG2C+ Vδ1+ γδ T cells only occurred coincident with CMV replication. For example, recipient M6 who did not experience CMV reactivation exhibited consistently lower proportions of this subset up to 18 months post-LTx period, despite ceasing antiviral prophylaxis at 160 days post-transplant. However, clearly the importance of this γδ T cell subset in preventing CMV reactivation is not apparent. Notably, this recipient had a very strong positive result from the QuantiFERON-CMV test (hence cessation of antivirals at 5.5 months), indicating a robust CMV-specific CD8+ T cell response and highlighting the likelihood that CMV control requires an orchestrated response from several immune compartments.

γδ T cells represent an under-researched population of immune cells with the potential to contribute to both CMV immunity as a therapy or diagnostic tool. Monitoring transplant recipients for the phenotype of γδ T cells could be highly relevant to develop novel therapies against CMV following transplantation. Moreover, this cell subset may have utility in therapies aimed at reducing other viral infections.
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Appendix. Supplementary materials {#sec0010}
=================================

**Supplementary Figure 1.** A) Cell sorting strategy for isolating Vγ9/Vδ2 neg γδ T cells (blue gate), showing flow cytometry plots of donor high-risk recipient H7 (subsequently TCR deep sequenced in Figure 3A). B) Total sequencing reads achieved for TRG and TRD sequencing in high-risk recipient H7 presented in Figure 3A. C) Deep sequencing TCR analysis from H7, showing TRG and TRD total unique clonotypes (left), D50 diversity index (middle) and the accumulated frequency the top 20 clonotypes occupied within the repertoire (right), analysed pre-LTx and post-LTx from the repertoires presented in Figure 3A.Image, image 1 **Supplementary Figure 2**. Changes in the proportions of Vδ1+ (A), NKG2C+ (B) and CD27low/CD45RA (C) γδ T cells in moderate risk recipients with CMV replication. Joined solid lines indicate changes in an individual recipient on standard antiviral prophylaxis whereas dashed lines between points are changes for moderate risk recipients on extended antiviral prophylaxis. Dashed vertical line indicates cessation of standard antiviral prophylaxis. Filled black circles and grey circles indicate positive CMV PCR in blood and BAL, respectively. Stars indicate positive CMV PCR in both blood and BAL. The 3 recipients with lower proportions of pre-LTx Vδ1+/NKG2C+/effector γδ T cells (M11, M12 and M15) are show in grey lines. wk=weeks, mo=months.Image, image 2 Image, application 3

Supplementary material associated with this article can be found in the online version at <https://doi.org/10.1016/j.healun.2020.08.014>.
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[^2]: D= donor, R= recipient, CMV= cytomegalovirus, + = CMV seropositive, - = CMV seronegative, BAL = bronchoalveolar lavage Superscript numbers indicate the timepoint post-transplant where the PCR positive result was obtained.

[^3]: indicates symptomatic CMV infection
